|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Majem M and Remon J: Tumor heterogeneity:
Evolution through space and time in EGFR mutant non small cell lung
cancer patients. Transl Lung Cancer Res. 2:226–237. 2013.PubMed/NCBI
|
|
4
|
Westover D, Zugazagoitia J, Cho BC, Lovly
CM and Paz-Ares L: Mechanisms of acquired resistance to first- and
second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29
(Suppl_1):i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clairmont CS, Sarangi P, Ponnienselvan K,
Galli LD, Csete I, Moreau L, Adelmant G, Chowdhury D, Marto JA and
D'Andrea AD: TRIP13 regulates DNA repair pathway choice through
REV7 conformational change. Nat Cell Biol. 22:87–96. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma HT and Poon RY: TRIP13 functions in the
establishment of the spindle assembly checkpoint by replenishing
O-MAD2. Cell Rep. 22:1439–1450. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye Q, Kim DH, Dereli I, Rosenberg SC,
Hagemann G, Herzog F, Tóth A, Cleveland DW and Corbett KD: The AAA+
ATPase TRIP13 remodels HORMA domains through N-terminal engagement
and unfolding. EMBO J. 36:2419–2434. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alfieri C, Chang L and Barford D:
Mechanism for remodelling of the cell cycle checkpoint protein MAD2
by the ATPase TRIP13. Nature. 559:274–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yost S, de Wolf B, Hanks S, Zachariou A,
Marcozzi C, Clarke M, de Voer R, Etemad B, Uijttewaal E, Ramsay E,
et al: Biallelic TRIP13 mutations predispose to Wilms tumor and
chromosome missegregation. Nat Genet. 49:1148–1151. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raina VB and Vader G: Homeostatic control
of meiotic prophase checkpoint function by Pch2 and Hop1. Curr
Biol. 30:4413–4424.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li C, Xia J, Franqui-Machin R, Chen F, He
Y, Ashby TC, Teng F, Xu H, Liu D, Gai D, et al: TRIP13 modulates
protein deubiquitination and accelerates tumor development and
progression of B cell malignancies. J Clin Invest. 131:e1468932021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sheng N, Yan L, Wu K, You W, Gong J, Hu L,
Tan G, Chen H and Wang Z: TRIP13 promotes tumor growth and is
associated with poor prognosis in colorectal cancer. Cell Death
Dis. 9:4022018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J,
Peng W, Wang X, Chen F and Cui H: TRIP13 promotes the cell
proliferation, migration and invasion of glioblastoma through the
FBXW7/c-MYC axis. Br J Cancer. 121:1069–1078. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou XY and Shu XM: TRIP13 promotes
proliferation and invasion of epithelial ovarian cancer cells
through notch signaling pathway. Eur Rev Med Pharmacol Sci.
23:522–529. 2019.PubMed/NCBI
|
|
15
|
Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y,
Zhang T, Zhou J and Wang P: TRIP13 is a predictor for poor
prognosis and regulates cell proliferation, migration and invasion
in prostate cancer. Int J Biol Macromol. 121:200–206. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu L, Xiao Y, Zhou X, Wang J, Chen S, Peng
T and Zhu X: TRIP13 interference inhibits the proliferation and
metastasis of thyroid cancer cells through regulating TTC5/p53
pathway and epithelial-mesenchymal transition related genes
expression. Biomed Pharmacother. 120:1095082019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai W, Ni W, Jin Y and Li Y: TRIP13
promotes lung cancer cell growth and metastasis through
AKT/mTORC1/c-Myc signaling. Cancer Biomark. 30:237–248. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li W, Zhang G, Li X, Wang X, Li Q, Hong L,
Shen Y, Zhao C, Gong X, Chen Y and Zhou J: Thyroid hormone receptor
interactor 13 (TRIP13) overexpression associated with tumor
progression and poor prognosis in lung adenocarcinoma. Biochem
Biophys Res Commun. 499:416–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li ZH, Lei L, Fei LR, Huang WJ, Zheng YW,
Yang MQ, Wang Z, Liu CC and Xu HT: TRIP13 promotes the
proliferation and invasion of lung cancer cells via the Wnt
signaling pathway and epithelial-mesenchymal transition. J Mol
Histol. 52:11–20. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Huang J, Li B, Xue H, Tricot G, Hu
L, Xu Z, Sun X, Chang S, Gao L, et al: A small-molecule inhibitor
targeting TRIP13 suppresses multiple myeloma progression. Cancer
Res. 80:536–548. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Banerjee R, Liu M, Bellile E, Schmitd LB,
Goto M, Hutchinson MN, Singh P, Zhang S, Damodaran DP, Nyati MK, et
al: Phosphorylation of TRIP13 at Y56 induces radiation resistance
but sensitizes head and neck cancer to cetuximab. Mol Ther.
30:468–484. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu S, Guo M, Fan Z, Chen Y, Shi X, Gu C
and Yang Y: Elevated TRIP13 drives cell proliferation and drug
resistance in bladder cancer. Am J Transl Res. 11:4397–4410.
2019.PubMed/NCBI
|
|
23
|
Levine B and Kroemer G: Biological
functions of autophagy genes: A disease perspective. Cell.
176:11–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Galluzzi L and Green DR:
Autophagy-independent functions of the autophagy machinery. Cell.
177:1682–1699. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dikic I and Elazar Z: Mechanism and
medical implications of mammalian autophagy. Nat Rev Mol Cell Biol.
19:349–364. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu M and Zhang P: EGFR-mediated autophagy
in tumourigenesis and therapeutic resistance. Cancer Lett.
469:207–216. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amaravadi RK, Kimmelman AC and Debnath J:
Targeting autophagy in cancer: Recent advances and future
directions. Cancer Discov. 9:1167–81. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheng WL, Feng PH, Lee KY, Chen KY, Sun
WL, Van Hiep N, Luo CS and Wu SM: The role of EREG/EGFR pathway in
tumor progression. Int J Mol Sci. 22:128282021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pao W and Miller VA: Epidermal growth
factor receptor mutations, small-molecule kinase inhibitors, and
non-small-cell lung cancer: Current knowledge and future
directions. J Clin Oncol. 23:2556–2568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Q, Yu S, Zhao W, Qin S, Chu Q and Wu
K: EGFR-TKIs resistance via EGFR-independent signaling pathways.
Mol Cancer. 17:532018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han W, Pan H, Chen Y, Sun J, Wang Y, Li J,
Ge W, Feng L, Lin X, Wang X, et al: EGFR tyrosine kinase inhibitors
activate autophagy as a cytoprotective response in human lung
cancer cells. PLoS One. 6:e186912011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li YY, Lam SK, Mak JC, Zheng CY and Ho JC:
Erlotinib-induced autophagy in epidermal growth factor receptor
mutated non-small cell lung cancer. Lung Cancer. 81:354–361. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gremke N, Polo P, Dort A, Schneikert J,
Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC,
Timofeev O, et al: mTOR-mediated cancer drug resistance suppresses
autophagy and generates a druggable metabolic vulnerability. Nat
Commun. 11:46842020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rong X, Liang Y, Han Q, Zhao Y, Jiang G,
Zhang X, Lin X, Liu Y, Zhang Y, Han X, et al: Molecular mechanisms
of tyrosine kinase inhibitor resistance induced by
membranous/cytoplasmic/nuclear translocation of epidermal growth
factor receptor. J Thorac Oncol. 14:1766–1783. 2019. View Article : Google Scholar : PubMed/NCBI
|
